Want to see KR:063160 full AI Analyst Report?
063160 Stock Chart & Stats
$12330.00
-$20.00(-0.16%)
―
--
Day’s Range― - ―
52-Week Range$11,770.00 - $24,900.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)29.26K
Market Cap
₩67.64B
Enterprise Value$219.49B
Total Cash (Recent Filing)₩587.63M
Total Debt (Recent Filing)₩147.94B
Price to Earnings (P/E)―
Beta0.18
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.46%
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,485,962
10 Day Avg. Volume7,993
30 Day Avg. Volume29,256
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)0.88
Price to Sales (P/S)0.70
P/FCF Ratio-10.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Integrated Drug PlatformCKD Bio combines drug development, manufacturing, and marketing within one operating platform. This integration can support control over product supply and commercialization while allowing the company to retain capabilities across the value chain as it develops and sells specialty and chronic-disease medicines.
Positive TTM EBITDAPositive EBITDA in the trailing period indicates that the business still generated earnings before depreciation, interest, and taxes despite weaker overall results. This provides an operating base that could support recovery if revenue stabilizes and profitability improves from currently depressed levels.
Substantial Equity BaseA sizable equity base relative to assets provides CKD Bio with a meaningful balance-sheet foundation and some capacity to absorb operating volatility. Although profitability has weakened, this capital base can offer greater resilience than a business funded primarily through debt.
Bears Say
Contracting RevenueRecent revenue contraction signals weaker demand, product performance, or commercial execution than in 2024. If the decline persists, it can reduce operating leverage, limit reinvestment capacity, and make it harder for CKD Bio to recover margins while funding pharmaceutical development.
Losses And Margin PressureThe shift from positive 2024 net income to larger losses and negative operating profit shows that profitability has deteriorated materially. Continued margin pressure would weaken internal funding for R&D and commercialization, while making a sustained earnings recovery more dependent on improved business performance.
Negative Free Cash FlowPersistent negative free cash flow indicates that recent operations have not funded the company’s cash needs internally. This reduces financial flexibility, increases reliance on available funding sources, and could constrain investment in products and capabilities if cash burn continues.
CKD Bio Corp. News
063160 FAQ
What was CKD Bio Corp.’s price range in the past 12 months?
CKD Bio Corp. lowest stock price was $11770.00 and its highest was $24900.00 in the past 12 months.
What is CKD Bio Corp.’s market cap?
CKD Bio Corp.’s market cap is ₩67.64B.
When is CKD Bio Corp.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CKD Bio Corp.’s earnings last quarter?
Currently, no data Available
Is CKD Bio Corp. overvalued?
According to Wall Street analysts CKD Bio Corp.’s price is currently Undervalued.
Does CKD Bio Corp. pay dividends?
CKD Bio Corp. pays a Notavailable dividend of $100 which represents an annual dividend yield of 0.46%. See more information on CKD Bio Corp. dividends here
What is CKD Bio Corp.’s EPS estimate?
CKD Bio Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CKD Bio Corp. have?
CKD Bio Corp. has 5,485,962 shares outstanding.
What happened to CKD Bio Corp.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CKD Bio Corp.?
Currently, no hedge funds are holding shares in KR:063160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CKD Bio Corp.
CKD Bio Corp., a South Korean company founded in 1941 and headquartered in Seoul, specializes in the production and distribution of pharmaceutical active ingredients (APIs). Their manufacturing processes leverage diverse technologies, including fermentation, chemical synthesis, and biotechnology. The company's extensive portfolio of APIs targets a broad spectrum of therapeutic applications, encompassing antibiotics, beta-lactamase inhibitors, immunosuppressants, oncology treatments, anti-obesity medications, dry eye remedies, antiviral and antituberculosis agents, antihyperlipidemics, and probiotics. Beyond its core manufacturing, CKD Bio Corp. also provides contract research, development, and manufacturing (CRDMO) services for APIs, pharmaceutical intermediates, and probiotic formulations. The company actively exports its products, establishing a global reach.
Technical Analysis
Aprogen Biologics
―
Celltrion Pharm Inc.
―
Daewoong Pharmaceutical Co., Ltd.
―
Dong-A ST Co., Ltd.
―
Enzychem Lifesciences Corp.
―